{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000159","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.788661+00:00","generated_at":"2026-06-08T06:18:51.056734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora expands KIO-301 Phase 2 development after positive ABACUS-1 results; Q3 net loss $5.8M","bullets":["ABACUS-1 Phase 1b showed KIO-301 safe, tolerable, with significant visual field improvements and increased brain activity on fMRI.","Company plans Phase 2 trials for RP (ABACUS-2), Choroideremia, and Stargardt disease in 2024.","Q3 2023 net loss $5.8M vs $5.1M in Q3 2022; loss increase driven by non-cash impairment of KIO-101/201.","Cash and equivalents $5.4M, plus $1.3M tax receivables; runway into May 2024; $9.6M available on equity line.","Raised $6.3M in funding and $1.2M in tax incentives during first half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000159","json":"https://secwatch.observer/filing/0001372514-23-000159.json","markdown":"https://secwatch.observer/filing/0001372514-23-000159.md","text":"https://secwatch.observer/filing/0001372514-23-000159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000159/0001372514-23-000159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000159/kprx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:18:51.056734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}